The United States will stop subsidizing vaccines and medication against COVID in 2023

Booster vaccination in Schwenksville, Pennsylvania (Reuters)

The United States Government estimates that it will run out of funds to buy and distribute vaccines and treatments against COVID at the beginning of 2023, so they will no longer be subsidized, and has already begun plans for the private sector to be in charge of market these products.

The Department of Health and Human Services (HHS) reported on Tuesday that, by January of next year, the americans they will have to start accessing vaccines and antiviral treatments through the “private market, similar to what happens with flu vaccines.”

Assistant Secretary for Preparedness and Response Dawn O’Connell said in a statement that while they already intended to transition to the private sector, plans have been accelerated due to the fact that they have not received additional funds from Congress.

“It has been more than 530 days since we received the last funds for the pandemic and without additional resources, it will be difficult to continue” delivering vaccines and treatments to Americans on a subsidized basis, O’Donell wrote in a statement.

“We have always intended to transition to the commercial market and have been planning to do so for some time,” he added.

Vaccination center in Lansdale, Pennsylvania (Reuters/file)
Vaccination center in Lansdale, Pennsylvania (Reuters/file)

Since the start of the pandemic, The United States government and pharmaceutical companies have gone from discussing the acquisition of vaccines and medicines against the coronavirus to selling them commercially, as is the case with those that immunize against seasonal flu.

Nevertheless, the Department already has 170 million booster doses for a vaccination campaign in the fall and winter, the official specified. Those booster shots are expected to be licensed for use later this week and offered to people for free. While it might meet current demand, it won’t be enough to immunize all adults in the long term.

Government projections estimate that reserves of the preventive treatment Evusheld and the antiviral drug Lagevrio will be exhausted in early 2023.

The lack of agreement on the part of the United States Congress to which O’Connell has previously mentioned has been reflected first in the blocking of some 15,000 million dollars by the Democrats of the House of Representatives in case they came from funds state. Subsequently, it was the Republicans in the Senate who refused to provide $10 billion due to objections to the immigration policies of the Biden Administration.

(With information from EFE and Europa Press)


Why those who have suffered from COVID are at higher risk of developing myocarditis
MIT researchers developed a home use test to predict immunity to COVID
They discover the key to combat all variants of COVID-19

infobae Sp

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button